Tourmaline Bio EBITDA 2020-2025 | TRML

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Tourmaline Bio ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Tourmaline Bio ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$69.3B
Zoetis (ZTS)	$67.6B
Takeda Pharmaceutical (TAK)	$47B
Daiichi Sankyo, - (DSNKY)	$46.1B
BeOne Medicines - (ONC)	$33.7B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$20B
Merck (MKKGY)	$16.8B
Shionogi (SGIOY)	$15.5B
United Therapeutics (UTHR)	$14B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.6B
Madrigal Pharmaceuticals (MDGL)	$8.3B
Corcept Therapeutics (CORT)	$7.7B
Grifols, S.A (GRFS)	$7.3B
Ionis Pharmaceuticals (IONS)	$6.9B
Stevanato Group S.p.A (STVN)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.3B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Hypermarcas (HYPMY)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.2B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B